Hit identification is the critical inflection point in radiopharmaceutical discovery, where validated molecular targets are translated into actionable chemical starting points through systematic screening of diverse compound libraries. Protheragen offers a comprehensive hit identification and screening platform that integrates high-throughput biophysical screening, virtual screening, and display technologies to rapidly uncover high-quality binders for your radiopharmaceutical drug conjugate programs.
Hit identification represents the transition from target validation to the discovery of chemical matter capable of modulating a biological target with sufficient affinity and selectivity. In radiopharmaceutical discovery, this stage carries additional complexity because the identified hits must not only bind the target effectively but also tolerate structural modification for chelator incorporation, maintain favorable physicochemical properties for radiolabeling, and exhibit biodistribution profiles compatible with both diagnostic imaging and therapeutic applications. The process typically employs a multi-pronged strategy combining high-throughput screening (HTS) of large compound libraries, virtual screening (VS) using computational docking and machine learning models, fragment-based screening for de novo design, and display technologies such as phage display or DNA-encoded libraries for peptide and biologic discovery.
Fig 1. Workflow from VS to lead compounds identification for radiotracer development. (Hsieh, Chia-Ju, et al., 2023)
Each approach offers distinct advantages: HTS provides empirical binding data across vast chemical space, VS enables rapid prioritization of billions of compounds without physical synthesis, and display technologies can access structural motifs beyond conventional small-molecule libraries. The convergence of these methods, guided by a well-designed screening cascade, maximizes the probability of identifying hits that can be successfully advanced through hit-to-lead optimization and ultimately converted into radiolabel-ready precursors.
The radiopharmaceutical hit identification landscape is undergoing rapid transformation, driven by technological innovation in screening platforms, the expansion of RDC modalities, and the integration of artificial intelligence into discovery workflows. The table below outlines the major screening approaches, their applications in radiopharmaceutical discovery, and the strategic considerations that guide their selection.
| Screening Platform | Key Capabilities | Radiopharmaceutical Applications |
|---|---|---|
| High-Throughput Screening (HTS) | Large-scale biochemical and cell-based assays using 384/1536-well formats; automated liquid handling; multimodal detection (fluorescence, luminescence, radioligand binding). | Identification of small-molecule binders for targets such as PSMA, SSTR, and integrins; scintillation proximity assays (SPA) for direct radioligand displacement; competition binding assays for affinity ranking. |
| Virtual Screening (VS) & AI-Driven Docking | Structure-based docking against crystal structures or homology models; ligand-based pharmacophore modeling; machine learning scoring functions; ultra-high-throughput screening of billions of compounds computationally. | Rapid prioritization of PET tracer candidates (e.g., 18F-PSMA-1007 analogs); prediction of blood-brain barrier permeability for neurological targets; identification of novel scaffolds for alpha-emitter conjugates. |
| Fragment-Based Screening (FBS) | Screening of low-molecular-weight fragments (150–300 Da) using NMR, X-ray crystallography, or surface plasmon resonance (SPR); detection of weak binding (mM to μM range) for subsequent elaboration. | De novo design of radiotracer cores with minimal structural complexity; identification of binding hot spots for chelator placement; construction of focused libraries around fragment hits for SAR expansion. |
| Phage Display & DNA-Encoded Libraries (DEL) | In vitro display of peptide or protein libraries on phage surfaces; DNA-encoded chemical libraries enabling FACS-based screening of massive libraries (10^9–10^12 variants); bead-based microfluidic platforms. | Discovery of cyclic peptide binders for oncology targets (PSMA, DLL3, GPC3); identification of tumor-targeting peptides with rapid renal clearance; development of antibody fragments (scFv, nanobodies) for RDCs. |
| Biophysical Screening (SPR, BLI, ITC) | Label-free real-time binding analysis using surface plasmon resonance (SPR), bio-layer interferometry (BLI), and isothermal titration calorimetry (ITC); determination of binding kinetics (kon, koff) and thermodynamics. | Validation of HTS hits and elimination of false positives; characterization of binding kinetics for radioligand design; assessment of chelator impact on binding affinity; ranking of lead series by residence time. |
| Cell-Based Phenotypic Screening | Functional assays measuring cellular responses (receptor internalization, second messenger activation, cytotoxicity) in target-expressing cell lines; high-content imaging for multiparametric analysis. | Evaluation of internalization kinetics for receptor-mediated endocytosis; assessment of radiopharmaceutical efficacy in cell killing assays; identification of compounds with favorable mechanism of action for therapy. |
| AI/ML-Predictive Screening | Deep learning models (CNNs, GANs, transformers) trained on molecular structures and biological data; prediction of binding affinity, ADMET properties, radiochemical yield, and biodistribution from chemical structure. | Virtual screening acceleration for PET radiotracers; prediction of optimal labeling precursors and synthetic routes; polypharmacology assessment to minimize off-target effects; generative design of novel RDC architectures. |
Protheragen delivers a comprehensive hit identification and screening platform purpose-built for radiopharmaceutical discovery, integrating high-throughput biochemical and cell-based screening, structure-based virtual screening, phage display technologies, and AI-driven predictive modeling to identify high-quality hits across small-molecule, peptide, and antibody-based modalities. Our multidisciplinary team ensures that every screening campaign is designed with radiopharmaceutical-specific endpoints in mind—from chelator incorporation feasibility and metabolic stability to tumor penetration and clearance kinetics—enabling rapid progression from validated target to optimized lead series ready for precursor design and radiolabeling evaluation.
We run automated 384/1536-well HTS to screen compound libraries against radiopharma targets via radioligand binding, SPA, fluorescence polarization and luminescence assays. Libraries are filtered for labeling-friendly structures fit for ¹⁸F, ¹¹C and radiometals. Orthogonal assays remove false positives and retain competitive binding hits for further optimization.
We combine molecular docking, pharmacophore modeling and machine learning to screen massive compound pools computationally. Deep learning predicts protein-ligand interactions and generates new molecular scaffolds. AI models are trained to assess radiotracer key traits like BBB permeability and tumor-muscle ratios, cutting synthetic workload and speeding up hit discovery.
Our phage display system screens linear, cyclic and constrained peptide libraries to find high-affinity binders for tumor antigens (PSMA, DLL3, GPC3 etc.) via FACS and microfluidics. Peptides are tested for stability, synthetic feasibility and chelator compatibility, ideal for peptide-based radiopharmaceutical conjugates with fast tumor uptake and favorable renal clearance.
SPR, BLI and ITC label-free testing measures binding kinetic parameters to confirm genuine target interactions and guide chemical modification. We check if chelator conjugation impairs binding, plus run competition, IRF and ex vivo occupancy assays to bridge in vitro results to in vivo performance.
Using target-overexpressing cell lines and high-content imaging, we test receptor endocytosis, compound internalization, cytotoxicity and subcellular distribution. Blocking and functional assays verify hits can trigger required biological effects to support radionuclide delivery or diagnostic imaging contrast.
For novel or poorly characterized targets, fragment screening with NMR, X-ray crystallography and SPR yields small molecular building blocks. We build focused libraries with late-stage radiolabeling handles, run parallel synthesis and early ADMET testing to build new scaffolds balancing binding affinity and radiochemical practicality.
Protheragen's hit identification and screening services are distinguished by our deep integration of radiochemistry expertise, advanced screening technologies, and AI-driven predictive modeling. We understand that successful radiopharmaceutical discovery requires hits that satisfy not only conventional drug-like criteria but also the unique demands of radiolabeling, in vivo stability, and theranostic translation. Our platform is designed to identify and validate hits with the highest probability of clinical success, accelerating your program from target to lead with scientific rigor and operational efficiency.
Whether you are initiating a new radiopharmaceutical discovery program or seeking to expand your existing hit portfolio, Protheragen is equipped to accelerate your journey from validated target to optimized lead series. Contact us today to discuss how our integrated hit identification and screening services can advance your RDC, small-molecule radiotracer, or peptide-based theranostic program. Reach out to our scientific team to schedule a consultation and explore a tailored partnership that aligns with your development timeline and strategic objectives.
Reference